Helus Pharma Inc.
HELPHealthcare|Medical - Pharmaceuticals|CA
$8.96
+0.57 (+6.79%)
DCF Value
$3.20
Next Earnings Report
Nov 12, 2026
EPS est. -$0.67
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (0)
No upcoming completion dates found in active trials.
Recent Press Releases
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
Nov 3, 2026 · GlobeNewsWire
Helus Pharma Announces Co-Founders' Transition from Executive Leadership as Company Advances Toward Next Stage of Development
Oct 27, 2026 · GlobeNewsWire
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Oct 21, 2026 · GlobeNewsWire
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
Oct 15, 2026 · GlobeNewsWire
Helus Pharma to Host Investor Presentation on October 21, 2026
Oct 8, 2026 · GlobeNewsWire
Helus Pharma Announces Completion of Legal Name Change
Oct 1, 2026 · GlobeNewsWire
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
Sep 22, 2026 · GlobeNewsWire
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
Sep 21, 2026 · GlobeNewsWire
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
Sep 21, 2026 · GlobeNewsWire
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
Sep 10, 2026 · GlobeNewsWire
SEC Filings (4)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.